Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. SNTA’s lead drug, ganetespib, has demonstrated anti-cancer activity in multiple targeted patient populations, including in lung cancer and breast cancer, and has shown a favorable safety profile in more than 600 patients treated to date. For more information, visit the company’s Web site: http://www.syntapharma.com

Let us hear your thoughts below: